This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Elamipretide treatment for 8 weeks almost completely reversed age-related increases in S-glutathionylation in mouse hearts.
Why it matters
Understanding how elamipretide reverses age-related changes in heart proteins could lead to new therapies for age-associated heart diseases. This research highlights potential interventions to improve heart health in older adults.
How the study worked
The study used shotgun proteomics to analyze the S-glutathionylation and phosphorylation of heart proteins in young and old mice, comparing the effects of elamipretide treatment.
What this study cannot tell us
The study was conducted in mice, so results may not directly translate to humans. Further research is needed to explore long-term effects and safety in humans.
Read the original research
Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins.
GeroScience, 43(5), 2395-2412
Citation
Whitson, Jeremy A; Martín-Pérez, Miguel; Zhang, Tong; Gaffrey, Matthew J; Merrihew, Gennifer E; Huang, Eric; White, Collin C; Kavanagh, Terrance J; Qian, Wei-Jun; Campbell, Matthew D; MacCoss, Michael J; Marcinek, David J; Villén, Judit; Rabinovitch, Peter S. (2021). Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins.. GeroScience, 43(5), 2395-2412. https://doi.org/10.1007/s11357-021-00447-6